Chhetri Dinesh K, Shapiro Nina L
Division of Head and Neck Surgery, UCLA School of Medicine, Los Angeles, CA 90095, USA.
Arch Otolaryngol Head Neck Surg. 2003 Oct;129(10):1081-5. doi: 10.1001/archotol.129.10.1081.
To assess the efficacy of treating juvenile recurrent respiratory papillomas with intralesional cidofovir using a scheduled treatment protocol.
Prospective case series.
Tertiary care academic medical center.
Of 5 pediatric patients with recurrent respiratory papillomas, 2 had severe recurrent papillomatosis requiring long-term therapy of laser ablations every 2 weeks prior to cidofovir treatments. The 3 other patients were newly diagnosed or had milder disease.
Intralesional cidofovir (1 mg/kg) was administered during each scheduled visit. The first 4 treatments were at 2-week intervals (week 0, 2, 4, and 6). Subsequent treatment intervals were each increased by 1 week (treatments took place at week 9, 13, 18, 24, etc). Concomitant laser ablation was used only for bulky lesions.
Papilloma stage and need for laser ablation at each scheduled visit.
The mean follow-up time was 66 weeks. The mean (SD) papilloma stage decreased from 9.2 (5.5) at initial presentation to 3.4 (2.6) within 2 weeks of the first injection (P<.05), and continued to decrease for the remaining of the follow-up period. Papilloma stage 0 was achieved in 4 of the 5 patients. The need for laser ablation of papillomas also decreased within 4 weeks of treatment initiation (P<.05). At 9 weeks, no patient required laser therapy. One patient was removed from the protocol after 58 weeks.
An intralesional treatment protocol with cidofovir and increasing intervals between scheduled treatment was successful the long-term management of juvenile respiratory papillomatosis.
采用既定治疗方案评估病灶内注射西多福韦治疗青少年复发性呼吸道乳头状瘤的疗效。
前瞻性病例系列研究。
三级医疗学术医学中心。
5例复发性呼吸道乳头状瘤患儿中,2例患有严重复发性乳头状瘤病,在接受西多福韦治疗前需要每2周进行一次激光消融的长期治疗。其他3例患者为新诊断病例或病情较轻。
在每次预定就诊时进行病灶内注射西多福韦(1mg/kg)。前4次治疗间隔为2周(第0、2、4和6周)。随后的治疗间隔每次增加1周(治疗在第9、13、18、24周等进行)。仅对较大的病灶进行联合激光消融。
每次预定就诊时的乳头状瘤分期及激光消融需求。
平均随访时间为66周。乳头状瘤平均(标准差)分期从初次就诊时的9.2(5.5)降至首次注射后2周内的3.4(2.6)(P<0.05),并在剩余随访期内持续下降。5例患者中有4例达到乳头状瘤0期。乳头状瘤激光消融需求在治疗开始后4周内也有所下降(P<0.05)。在第9周时,无患者需要激光治疗。1例患者在58周后退出研究方案。
采用西多福韦病灶内治疗方案并增加预定治疗间隔时间,在青少年呼吸道乳头状瘤病的长期管理中取得了成功。